Optison™ Albumin Microspheres in Ultrasound-Assisted Gene Therapy and Drug Delivery

Jackson, Alexander; Castle, Jason; Smith, Adrian; Kalli, Christina

doi:10.1007/978-981-10-2116-9_7

Cited by 3 publications

(1 citation statement)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Optison was launched as the first of the second-generation of UCA in the North American market in January 1998 and in Europe in May of the same year (Jackson et al 2016). It is indicated for use in patients with suboptimal echocardiograms to opacify the LV and to improve the delineation of left ventricular endocardial borders (Fig.…”

Section: Optisonmentioning

confidence: 99%

Three Decades of Ultrasound Contrast Agents: A Review of the Past, Present and Future Improvements

Frinking

Segers

Luan

et al. 2020

Ultrasound in Medicine & Biology

206

128

View full text Add to dashboard Cite

Initial reports from the 1960s describing the observations of ultrasound contrast enhancement by tiny gaseous bubbles during echocardiographic examinations prompted the development of the first ultrasound contrast agent in the 1980s. Current commercial contrast agents for echography, such as Definity, Optison, Sonazoid and SonoVue, have proven to be successful in a variety of on-and off-label clinical indications. Whereas contrast-specific technology has seen dramatic progress after the introduction of the first approved agents in the 1990s, successful clinical translation of new developments has been limited during the same period, while understanding of microbubble physical, chemical and biologic behavior has improved substantially. It is expected that for a successful development of future opportunities, such as ultrasound molecular imaging and therapeutic applications using microbubbles, new creative developments in microbubble engineering and production dedicated to further optimizing microbubble performance are required, and that they cannot rely on bubble technology developed more than 3 decades ago.

show abstract

Section: Optisonmentioning

confidence: 99%

Three Decades of Ultrasound Contrast Agents: A Review of the Past, Present and Future Improvements

Frinking

Segers

Luan

et al. 2020

Ultrasound in Medicine & Biology

206

128

View full text Add to dashboard Cite

show abstract

Ultrasound Molecular Imaging and Drug Delivery

Caskey

2017

Mol Imaging Biol

View full text Add to dashboard Cite

Ultrasound is a rapidly advancing field with many emerging diagnostic and therapeutic applications. For diagnostics, new vascular targets are routinely identified and mature technologies are being translated to humans, while other recent innovations may bring about the creation of acoustic reporter genes and micron-scale resolution with ultrasound. As a cancer therapy, ultrasound is being explored as an adjuvant to immune therapies and to deliver acoustically or thermally active drugs to tumor regions. Ultrasound-enhanced delivery across the blood brain barrier (BBB) could potentially be very impactful for brain cancers and neurodegenerative diseases where the BBB often impedes the delivery of therapeutic molecules. In this minireview, we provide an overview of these topics in the field of ultrasound that are especially relevant to the interests of World Molecular Imaging Society.

show abstract